Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CB | P42338 | 20/20 | 0.68 |
| ▸ | PIK3CD | O00329 | 17/20 | 0.68 |
| ▸ | PIK3CA | P42336 | 16/20 | 0.68 |
| ▸ | PIK3CG | P48736 | 2/20 | 0.64 |
| ▸ | PIK3R1 | P27986 | 1/20 | 0.64 |
| ▸ | CSNK1A1 | P48729 | 1/20 | 0.64 |
| ▸ | PTK2 | Q05397 | 1/20 | 0.64 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.64 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL880820 | 0.90 | PIK3CB (0.73) | PIK3CBPIK3CDPIK3CAPIK3CGPIK3R1 | |
| SCHEMBL4355256 | 0.87 | PIK3CA (0.67) | PIK3CBPIK3CDPIK3CAPIK3CGPIK3R1 | |
| SCHEMBL13752211 | 0.86 | PIK3CB (0.69) | PIK3CBPIK3CDPIK3CAPIK3CGPIK3R1 | |
| SCHEMBL13752208 | 0.83 | PIK3CB (0.70) | PIK3CBPIK3CDPIK3CAPIK3CGPIK3R1 | |
| SCHEMBL5870416 | 0.82 | PIK3CB (0.59) | PIK3CBPIK3CDPIK3CAPIK3CGPIK3R1 | |
| SCHEMBL13752216 | 0.81 | PIK3CB (0.71) | PIK3CBPIK3CDPIK3CAPIK3CGPIK3R1 | |
| SCHEMBL5870441 | 0.80 | PIK3CB (0.61) | PIK3CBPIK3CDPIK3CAPIK3CGPIK3R1 | |
| SCHEMBL909777 | 0.80 | PIK3CB (0.77) | PIK3CBPIK3CDPIK3CAPIK3CGPIK3R1 | |
| SCHEMBL13752214 | 0.79 | PIK3CB (0.69) | PIK3CBPIK3CDPIK3CAPIK3CGPIK3R1 | |
| SCHEMBL25384916 | 0.79 | PIK3CB (0.61) | PIK3CBPIK3CDPIK3CAPIK3CGPIK3R1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12441736-B2 | KIF18A inhibitors | AMGEN INC. (US) | 2025-10-14 | — | — | US | disclosed |
| US-12054476-B2 | KIF18A inhibitors | AMGEN INC. (US) | 2024-08-06 | — | — | US | disclosed |
| CN-117940133-A | Therapeutic agents for degradation of mutant BRAF | C4医药公司 | 2024-04-26 | — | — | CN | disclosed |
| WO-2023215256-A1 | SOS1 INHIBITORS AND USES THEREOF | Revolution Medicines, Inc. (US) | 2023-11-09 | — | — | WO | disclosed |
| EP-4149477-A1 | TREATMENT OF THROMBOSIS AND ASSOCIATED DISORDERS WITH AN ANTI-PLATELET AGENT | The Heart Research Institute Ltd (AU) | 2023-03-22 | — | — | EP | disclosed |
| US-20220106293-A1 | KIF18A INHIBITORS | AMGEN INC. (US) | 2022-04-07 | — | — | US | disclosed |
| US-20220002311-A1 | KIF18A INHIBITORS | AMGEN INC. (US) | 2022-01-06 | — | — | US | disclosed |
| WO-2021226677-A1 | TREATMENT OF THROMBOSIS AND ASSOCIATED DISORDERS WITH AN ANTI-PLATELET AGENT. | THE HEART RESEARCH INSTITUTE LTD (AU) | 2021-11-18 | — | — | WO | disclosed |
| WO-2021081212-A1 | PYRIDOPYRIMIDINE DERIVATIVES USEFUL AS KRAS G12C AND KRAS G12D INHIBITORS IN THE TREATMENT OF CANCER | AMGEN INC. (US) | 2021-04-29 | — | — | WO | disclosed |
| US-20200239486-A1 | PYRIMIDINE-BASED COMPOUNDS FOR THE TREATMENT OF CANCER | G1 THERAPEUTICS, INC. (US) | 2020-07-30 | — | — | US | disclosed |
| US-20160117439-A1 | SUPERIOR BIOINFORMATICS PROCESS FOR IDENTIFYING AT RISK SUBJECT POPULATIONS | KONINKLIJKE PHILIPS N.V. (NL) | 2016-04-28 | — | — | US | disclosed |
| WO-2015157122-A1 | MERTK-SPECIFIC PYRAZOLOPYRIMIDINE COMPOUNDS | THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL (US) | 2015-10-15 | — | — | WO | disclosed |
| WO-2011056930-A2 | FRAGILE X MENTAL RETARDATION PROTEIN (FMRP), COMPOSITIONS, AND METHODS RELATED THERETO | EMORY UNIVERSITY (US) | 2011-05-12 | — | — | WO | disclosed |
| US-7598377-B2 | (+-)-7-Methyl-2-morpholin-4-yl-9-(1-phenylaminoethyl)-pyrido[1,2-a]pyrimidin-4-one, for example; selective inhibitors of phosphoinositide (PI) 3-kinase beta for use in anti-thrombotic therapy | ASTRAZENECA AB (SE) | 2009-10-06 | — | — | US | disclosed |
| US-20060276470-A1 | (+-)-7-Methyl-2-morpholin-4-yl-9-(1-phenylaminoethyl)-pyrido[1,2-a]pyrimidin-4-one, for example; selective inhibitors of phosphoinositide (PI) 3-kinase beta for use in anti-thrombotic therapy | ASTRAZENECA AB (SE) | 2006-12-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12441736-B2 | KIF18A inhibitors | KIF18A, KIF18B, KIF15 | PIK3CB 192/4885PIK3CD 265/4885PIK3CA 248/4885 |
| US-20220106293-A1 | KIF18A INHIBITORS | KIF18A, KIF18B, KIF15 | PIK3CB 182/4885PIK3CD 253/4885PIK3CA 244/4885 |
| US-20220002311-A1 | KIF18A INHIBITORS | KIF18A, KIF18B, KIF15 | PIK3CB 192/4885PIK3CD 265/4885PIK3CA 248/4885 |
| US-20200239486-A1 | PYRIMIDINE-BASED COMPOUNDS FOR THE TREATMENT OF CANCER | TYMS, TYMP, DPYD | PIK3CB 619/4885PIK3CD 1173/4885PIK3CA 308/4885 |
| US-12054476-B2 | KIF18A inhibitors | KIF18A, KIF18B, KIF15 | PIK3CB 182/4885PIK3CD 253/4885PIK3CA 244/4885 |
| US-20060276470-A1 | (+-)-7-Methyl-2-morpholin-4-yl-9-(1-phenylaminoethyl)-pyrido[1,2-a]pyrimidin-4-one, for example; selective inhibitors of phosphoinositide (PI) 3-kinase beta for use in anti-thrombotic therapy | PI4KA, PI4KB, PI4K2B | PIK3CB 8/4885PIK3CD 15/4885PIK3CA 16/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.